Related Experiment Video
Updated: May 29, 2026
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration
1Department of Pharmaceutical & Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA.
Abstract:
Sphingosine kinases (SK) regulate the balance between proapoptotic ceramides and mitogenic sphingosine-1-phosphate (S1P); however, the functions of the two isoenzymes (SK1 and SK2) in tumor cells are not well defined. Therefore, RNA interference was used to assess the individual roles of SK1 and SK2 in tumor cell sphingolipid metabolism, proliferation, and migration/invasion. Treatment of A498, Caki-1, or MDA-MB-231 cells with siRNAs specific for SK1 or SK2 effectively suppressed the expression of the target mRNA and protein. Ablation of SK1 did not affect mRNA or protein levels of SK2 and reduced intracellular levels of S1P while elevating ceramide levels. In contrast, ablation of SK2 elevated mRNA, protein, and activity levels of SK1 and increased cellular S1P levels. Interestingly, cell proliferation and migration/invasion were suppressed more by SK2-selective ablation than by SK1-selective ablation, showing that the increased S1P does not rescue these phenotypes. Similarly, exogenous S1P did not rescue the cells from the antiproliferative or antimigratory effects of the siRNAs. Consistent with these results, differential effects of SK1- and SK2-selective siRNAs on signaling proteins, including p53, p21, ERK1, ERK2, FAK, and VCAM1, indicate that SK1 and SK2 have only partially overlapping functions in tumor cells. Overall, these data indicate that loss of SK2 has stronger anticancer effects than does suppression of SK1. Consequently, selective inhibitors of SK2 may provide optimal targeting of this pathway in cancer chemotherapy.
Insights
Targeting sphingosine kinases (SK) in cancer shows promise. Loss of SK2 significantly inhibits tumor cell proliferation and invasion more than SK1 loss, suggesting SK2 as a key therapeutic target.
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Sphingosine kinases (SK) are crucial enzymes regulating sphingolipid metabolism.
- SK isoenzymes, SK1 and SK2, have distinct roles in cellular processes.
- Their specific functions in tumor cells and cancer progression remain incompletely understood.
Purpose of the Study:
- To elucidate the individual roles of SK1 and SK2 in tumor cell sphingolipid metabolism, proliferation, and migration/invasion.
- To compare the anticancer effects of selectively inhibiting SK1 versus SK2.
- To identify potential therapeutic strategies targeting SK isoenzymes in cancer.
Main Methods:
- RNA interference (siRNA) was employed to selectively suppress SK1 or SK2 expression in human cancer cell lines (A498, Caki-1, MDA-MB-231).
- Sphingolipid levels (S1P, ceramides), cell proliferation, and migration/invasion assays were performed.
- Expression and activity of SK isoenzymes and key signaling proteins were analyzed.
Main Results:
- Selective ablation of SK1 reduced S1P and increased ceramides, while SK2 ablation upregulated SK1 expression, activity, and S1P levels.
- SK2-selective ablation demonstrated a more potent suppression of tumor cell proliferation and migration/invasion compared to SK1 ablation.
- Exogenous sphingosine-1-phosphate (S1P) did not rescue the antiproliferative or antimigratory effects induced by siRNA treatment.
- Differential impacts on signaling proteins (p53, p21, ERK, FAK, VCAM1) highlight partially overlapping functions of SK1 and SK2.
Conclusions:
- Loss of SK2 exhibits stronger anticancer effects than the suppression of SK1.
- SK2 plays a more critical role in promoting tumor cell proliferation and invasion than SK1.
- Targeting SK2 with selective inhibitors may represent an optimal therapeutic strategy for cancer chemotherapy.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...